Charles Schwab Investment Management Inc. Has $68,000 Stock Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Charles Schwab Investment Management Inc. lessened its position in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 29.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,048 shares of the company’s stock after selling 15,411 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Outlook Therapeutics were worth $68,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in OTLK. State Street Corp raised its holdings in Outlook Therapeutics by 10.0% during the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock worth $1,242,000 after purchasing an additional 21,201 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Outlook Therapeutics during the 3rd quarter worth approximately $199,000. Barclays PLC raised its stake in shares of Outlook Therapeutics by 677.4% during the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock worth $111,000 after buying an additional 18,249 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Outlook Therapeutics by 49.2% in the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after buying an additional 112,812 shares during the period. Finally, Rhumbline Advisers boosted its stake in Outlook Therapeutics by 1,329.6% in the fourth quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock valued at $355,000 after acquiring an additional 174,896 shares during the last quarter. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Price Performance

Shares of NASDAQ OTLK opened at $1.22 on Wednesday. Outlook Therapeutics, Inc. has a twelve month low of $0.87 and a twelve month high of $10.95. The stock has a market cap of $39.06 million, a price-to-earnings ratio of -0.16 and a beta of 0.54. The company’s fifty day moving average is $1.63 and its 200-day moving average is $3.13.

Outlook Therapeutics (NASDAQ:OTLK) last posted its earnings results on Friday, February 14th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.04). On average, research analysts anticipate that Outlook Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Chardan Capital reiterated a “neutral” rating and set a $3.00 target price on shares of Outlook Therapeutics in a research report on Tuesday, February 18th. Guggenheim reaffirmed a “buy” rating and set a $12.00 price objective on shares of Outlook Therapeutics in a research note on Friday, January 17th. Ascendiant Capital Markets cut their target price on Outlook Therapeutics from $33.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, February 24th. Finally, HC Wainwright decreased their target price on Outlook Therapeutics from $30.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Outlook Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $10.20.

Outlook Therapeutics Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.